|
"su yy"的相關文件
顯示項目 21-30 / 68 (共7頁)
<< < 1 2 3 4 5 6 7 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
|
Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-11 |
Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
|
Su, YY;Lin, MY;Cheng, SM;Chang, WL;Yeh, CM;Yu, CC;Hsu, CW;Shan, YS;Huang, DY;Chen, LT |
| 國家衛生研究院 |
2023-06-08 |
The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study
|
Su, YY;Chao, YJ;Wang, CJ;Liao, TK;Su, PJ;Huang, CJ;Chiang, NJ;Yu, YT;Tsai, HM;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2023-06 |
Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS)
|
Chen, TWW;Hsu, CL;Wu, YC;Ou, DL;Su, YY;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: Focusing on hepatic safety and viral kinetics
|
Chen, SC;Tsou, HHS;Lee, TY;Wang, HW;Chen, YH;Wang, TE;Su, YY;Yang, S;Chiu, CF;Liu, TW;Cheng, AL;Chen, LT;Hsu, C |
| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2023-02 |
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
|
Su, YY;Chiang, NJ;Chang, JS;Wang, YW;Shen, BN;Li, YJ;Hwang, DY;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2023-01-30 |
Investigation into the content of red material in EUS-guided pancreatic cancer biopsies
|
Lin, MY;Su, YY;Yu, YT;Huang, CJ;Sheu, BS;Chang, WL |
| 國家衛生研究院 |
2022-11-15 |
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Li, CP;Yang, SH;Su, YY;Chiu, SC;Bai, LY;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-10 |
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression
|
Liu, TH;Chen, SC;Rau, KM;Lu, LC;Lin, PT;Su, YY;Teng, W;Lai, SW;Yehn, RH;Kao, TM;Lee, PC;Wu, CJ;Chen, CH;Hsu, CH;Lin, SM;Huang, YH;Chen, LT;Cheng, AL;Shen, YC |
顯示項目 21-30 / 68 (共7頁)
<< < 1 2 3 4 5 6 7 > >>
每頁顯示[10|25|50]項目
|
